ID 689 - Kwas dokozaheksaenowy

PL: Kwas dokozaheksaenowy
EN: Docosahexaenoic acid (DHA)
Pdf: docosahexaenoic acid

Oświadczenie (4)

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claims is docosahexaenoic acid (DHA), which is a well characterised n-3 long-chain fatty acid that can be quantified in foods by established methods. The absorption of DHA is well documented. This evaluation applies to all sources of DHA in the specified amounts.
The Panel considers that the food constituent, DHA, which is the subject of the health claims is sufficiently characterised.

2.4. Rozwój mózgu, oczu i nerwów (ID 627, 689, 704, 742, 3148, 3151)

The claimed effects are “brain, eye and nerve development”, “optimisation of brain maturation”, “brain development and function”, “human neurodevelopment”, “brain health and function”, and “maternal health”.
Brain, eye and nerve development is interpreted by the Panel as children‟s development. The Panel notes that claims related to children‟s development and health are outside the scope of Article 13 of Regulation (EC) No 1924/2006.

2.5. Utrzymanie prawidłowego funkcjonowania mózgu (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151)

The claimed effects are “mental state and performance”, “DHA plays an important role in cognitive functions at any stage of life”, “brain health and function”, “optimisation of brain maturation”, “brain development and function”, “human neurodevelopment”, “maternal health” and “cognitive function in the elderly”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effect refers to the maintenance of normal brain function.
The Panel considers that maintenance of normal brain function is a beneficial physiological effect.

3.4. Utrzymanie prawidłowego funkcjonowania mózgu (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151)

Deficiency of alpha linolenic acid, the parent fatty acid of the longer chain n-3 polyunsaturated fatty acids, including DHA, results in adverse clinical symptoms, including neurological abnormalities and poor growth (IoM, 2005). Evidence for the essentiality of n-3 fatty acids in humans can be drawn from case reports of patients receiving parenteral nutrition with intravenous lipids devoid of such fatty acids. Biochemical changes of n-3 fatty acids deficiency include a decrease in plasma and tissue DHA concentrations. There is no accepted cut-off concentration of plasma or tissue DHA concentrations below which functions ascribed to n-3 fatty acids such as visual or neurological functions are impaired (IoM, 2005). DHA is the major structural lipid in brain tissue and the central nervous system, and the membrane lipids of brain grey matter and the retina contain very high concentrations of DHA.
The Panel notes that there is a well established role of DHA in brain function.
The Panel concludes that a cause and effect relationship has been established between the consumption of DHA and the maintenance of normal brain function.

4.2. Utrzymanie prawidłowego funkcjonowania mózgu (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151)

The Panel considers that the following wording reflects the scientific evidence: “DHA contributes to the maintenance of normal brain function.”

5.2. Utrzymanie prawidłowego funkcjonowania mózgu (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151)

The Panel considers that, in order to bear the claim, foods should contain 250 mg of DHA in one or more servings. Such amounts can be consumed as part of a balanced diet. The target population is the general population.

Warunki i możliwe ograniczenia stosowania oświadczenia

55 - 160 mg per day